IL15 and neoplasm: The second modification was the introduction of a membrane-bound IL-15/IL15R fusion protein (IL-15RF) to enhance in vivo persistence, and the third modification was the addition of an anti-CD19 CAR optimized for NK cells for direct tumor targeting.